IL1B and Autoimmunity: Some agents targeting IL-1β, such as IL-1 receptor antagonist, soluble decoy IL-1 receptor and neutralizing monoclonal antibodies against IL-1, have been approved in clinics to treat autoimmunity or inflammatory diseases (32, 33).